TransMedics Group (NASDAQ:TMDX) Price Target Raised to $170.00 at Piper Sandler

TransMedics Group (NASDAQ:TMDX) had its price objective increased by Piper Sandler from $120.00 to $170.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have an overweight rating on the stock.

A number of other brokerages also recently issued reports on TMDX. Cantor Fitzgerald assumed coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They set an overweight rating and a $161.00 price objective for the company. Canaccord Genuity Group boosted their price objective on shares of TransMedics Group from $102.00 to $117.00 and gave the company a buy rating in a research report on Wednesday, May 1st. Oppenheimer boosted their price objective on shares of TransMedics Group from $105.00 to $125.00 and gave the company an outperform rating in a research report on Wednesday, May 1st. TD Cowen boosted their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the company a buy rating in a research report on Friday, June 7th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the company an overweight rating in a research report on Wednesday, May 1st. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $146.38.

TransMedics Group Price Performance

Shares of TMDX opened at $144.40 on Monday. The firm has a market cap of $4.76 billion, a PE ratio of -424.71 and a beta of 1.98. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. The firm has a fifty day simple moving average of $141.75 and a two-hundred day simple moving average of $105.95. TransMedics Group has a 1-year low of $36.42 and a 1-year high of $154.75.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The business had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. During the same period in the previous year, the business earned ($0.08) EPS. The company’s quarterly revenue was up 132.9% compared to the same quarter last year. On average, equities analysts anticipate that TransMedics Group will post 0.81 EPS for the current year.

Insiders Place Their Bets

In other TransMedics Group news, Director David Weill sold 2,500 shares of the stock in a transaction on Friday, May 10th. The stock was sold at an average price of $129.82, for a total value of $324,550.00. Following the completion of the sale, the director now owns 11,193 shares in the company, valued at approximately $1,453,075.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director David Weill sold 2,500 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $129.82, for a total transaction of $324,550.00. Following the completion of the transaction, the director now owns 11,193 shares in the company, valued at $1,453,075.26. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $145.17, for a total value of $1,252,091.25. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $8,948,714.31. The disclosure for this sale can be found here. In the last quarter, insiders sold 247,667 shares of company stock worth $30,087,968. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Venturi Wealth Management LLC purchased a new position in shares of TransMedics Group during the first quarter valued at about $30,000. Fidelis Capital Partners LLC purchased a new position in shares of TransMedics Group during the first quarter valued at about $35,000. J.Safra Asset Management Corp grew its position in shares of TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares in the last quarter. First Horizon Advisors Inc. grew its position in shares of TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after purchasing an additional 222 shares in the last quarter. Finally, RiverPark Advisors LLC grew its position in shares of TransMedics Group by 19.5% during the fourth quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock valued at $104,000 after purchasing an additional 215 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.